ABL1 is an inclusion eligibility criterion in 23 clinical trials for hodgkin lymphoma, of which 12 are open and 11 are closed. Of the trials that contain ABL1 status and hodgkin lymphoma as inclusion criteria, 1 is early phase 1 (0 open), 9 are phase 1 (4 open), 2 are phase 1/phase 2 (2 open), 10 are phase 2 (6 open), and 1 is no phase specified (0 open) [3].

AFF1 is an inclusion eligibility criterion in 22 clinical trials for hodgkin lymphoma, of which 13 are open and 9 are closed. Of the trials that contain AFF1 status and hodgkin lymphoma as inclusion criteria, 1 is early phase 1 (0 open), 9 are phase 1 (4 open), 2 are phase 1/phase 2 (2 open), 9 are phase 2 (7 open), and 1 is no phase specified (0 open) [3].

ALK is an inclusion eligibility criterion in 1 clinical trial for hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ALK status and hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

ASXL1 is altered in 1.79% of hodgkin lymphoma patients [2].

ASXL1 is an inclusion eligibility criterion in 4 clinical trials for hodgkin lymphoma, of which 4 are open and 0 are closed. Of the trials that contain ASXL1 status and hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 2 are phase 2 (2 open) [3].

BCL2 is altered in 1.82% of hodgkin lymphoma patients [2].

BCL2 is an inclusion eligibility criterion in 3 clinical trials for hodgkin lymphoma, of which 1 is open and 2 are closed. Of the trials that contain BCL2 status and hodgkin lymphoma as inclusion criteria, 3 are phase 1 (1 open) [3].

BCL6 is altered in 1.82% of hodgkin lymphoma patients [2].

BCL6 is an inclusion eligibility criterion in 3 clinical trials for hodgkin lymphoma, of which 1 is open and 2 are closed. Of the trials that contain BCL6 status and hodgkin lymphoma as inclusion criteria, 3 are phase 1 (1 open) [3].

BCR is an inclusion eligibility criterion in 23 clinical trials for hodgkin lymphoma, of which 12 are open and 11 are closed. Of the trials that contain BCR status and hodgkin lymphoma as inclusion criteria, 1 is early phase 1 (0 open), 9 are phase 1 (4 open), 2 are phase 1/phase 2 (2 open), 10 are phase 2 (6 open), and 1 is no phase specified (0 open) [3].

BRAF is an inclusion eligibility criterion in 1 clinical trial for hodgkin lymphoma, of which 0 are open and 1 is closed. Of the trial that contains BRAF status and hodgkin lymphoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

CBFA2T3 is an inclusion eligibility criterion in 1 clinical trial for hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains CBFA2T3 status and hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

CBFB is an inclusion eligibility criterion in 6 clinical trials for hodgkin lymphoma, of which 2 are open and 4 are closed. Of the trials that contain CBFB status and hodgkin lymphoma as inclusion criteria, 5 are phase 1 (2 open) and 1 is no phase specified (0 open) [3].

CCND1 is an inclusion eligibility criterion in 1 clinical trial for hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains CCND1 status and hodgkin lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

CREBBP is altered in 1.75% of hodgkin lymphoma patients [2].

CREBBP is an inclusion eligibility criterion in 2 clinical trials for hodgkin lymphoma, of which 2 are open and 0 are closed. Of the trials that contain CREBBP status and hodgkin lymphoma as inclusion criteria, 2 are phase 2 (2 open) [3].

DEK is an inclusion eligibility criterion in 20 clinical trials for hodgkin lymphoma, of which 11 are open and 9 are closed. Of the trials that contain DEK status and hodgkin lymphoma as inclusion criteria, 1 is early phase 1 (0 open), 9 are phase 1 (4 open), 2 are phase 1/phase 2 (2 open), 7 are phase 2 (5 open), and 1 is no phase specified (0 open) [3].

DNMT3A is altered in 1.79% of hodgkin lymphoma patients [2].

DNMT3A is an inclusion eligibility criterion in 1 clinical trial for hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains DNMT3A status and hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

ELL is an inclusion eligibility criterion in 21 clinical trials for hodgkin lymphoma, of which 12 are open and 9 are closed. Of the trials that contain ELL status and hodgkin lymphoma as inclusion criteria, 1 is early phase 1 (0 open), 9 are phase 1 (4 open), 2 are phase 1/phase 2 (2 open), 8 are phase 2 (6 open), and 1 is no phase specified (0 open) [3].

ETV6 is an inclusion eligibility criterion in 2 clinical trials for hodgkin lymphoma, of which 2 are open and 0 are closed. Of the trials that contain ETV6 status and hodgkin lymphoma as inclusion criteria, 2 are phase 2 (2 open) [3].

FGFR3 is an inclusion eligibility criterion in 2 clinical trials for hodgkin lymphoma, of which 2 are open and 0 are closed. Of the trials that contain FGFR3 status and hodgkin lymphoma as inclusion criteria, 2 are phase 1 (2 open) [3].

FLT3 is an inclusion eligibility criterion in 23 clinical trials for hodgkin lymphoma, of which 12 are open and 11 are closed. Of the trials that contain FLT3 status and hodgkin lymphoma as inclusion criteria, 1 is early phase 1 (0 open), 10 are phase 1 (4 open), 2 are phase 1/phase 2 (2 open), 9 are phase 2 (6 open), and 1 is no phase specified (0 open) [3].

GLIS2 is an inclusion eligibility criterion in 1 clinical trial for hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains GLIS2 status and hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

HIP1 is an inclusion eligibility criterion in 1 clinical trial for hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains HIP1 status and hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

HOXA9 is an inclusion eligibility criterion in 1 clinical trial for hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains HOXA9 status and hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

IGH is an inclusion eligibility criterion in 4 clinical trials for hodgkin lymphoma, of which 4 are open and 0 are closed. Of the trials that contain IGH status and hodgkin lymphoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].

IKZF1 is altered in 1.82% of hodgkin lymphoma patients [2].

IKZF1 is an inclusion eligibility criterion in 2 clinical trials for hodgkin lymphoma, of which 1 is open and 1 is closed. Of the trials that contain IKZF1 status and hodgkin lymphoma as inclusion criteria, 2 are phase 2 (1 open) [3].

KAT6A is an inclusion eligibility criterion in 1 clinical trial for hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains KAT6A status and hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

KDM5A is an inclusion eligibility criterion in 1 clinical trial for hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains KDM5A status and hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

KIT is an inclusion eligibility criterion in 7 clinical trials for hodgkin lymphoma, of which 3 are open and 4 are closed. Of the trials that contain KIT status and hodgkin lymphoma as inclusion criteria, 5 are phase 1 (2 open), 1 is phase 2 (1 open), and 1 is no phase specified (0 open) [3].

KMT2A is an inclusion eligibility criterion in 22 clinical trials for hodgkin lymphoma, of which 13 are open and 9 are closed. Of the trials that contain KMT2A status and hodgkin lymphoma as inclusion criteria, 1 is early phase 1 (0 open), 9 are phase 1 (4 open), 2 are phase 1/phase 2 (2 open), 9 are phase 2 (7 open), and 1 is no phase specified (0 open) [3].

MAF is an inclusion eligibility criterion in 2 clinical trials for hodgkin lymphoma, of which 2 are open and 0 are closed. Of the trials that contain MAF status and hodgkin lymphoma as inclusion criteria, 2 are phase 1 (2 open) [3].

MAFB is an inclusion eligibility criterion in 2 clinical trials for hodgkin lymphoma, of which 2 are open and 0 are closed. Of the trials that contain MAFB status and hodgkin lymphoma as inclusion criteria, 2 are phase 1 (2 open) [3].

MECOM is an inclusion eligibility criterion in 23 clinical trials for hodgkin lymphoma, of which 14 are open and 9 are closed. Of the trials that contain MECOM status and hodgkin lymphoma as inclusion criteria, 1 is early phase 1 (0 open), 9 are phase 1 (4 open), 2 are phase 1/phase 2 (2 open), 10 are phase 2 (8 open), and 1 is no phase specified (0 open) [3].

MLF1 is an inclusion eligibility criterion in 8 clinical trials for hodgkin lymphoma, of which 5 are open and 3 are closed. Of the trials that contain MLF1 status and hodgkin lymphoma as inclusion criteria, 1 is early phase 1 (0 open), 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 5 are phase 2 (4 open) [3].

MLLT1 is an inclusion eligibility criterion in 21 clinical trials for hodgkin lymphoma, of which 12 are open and 9 are closed. Of the trials that contain MLLT1 status and hodgkin lymphoma as inclusion criteria, 1 is early phase 1 (0 open), 9 are phase 1 (4 open), 2 are phase 1/phase 2 (2 open), 8 are phase 2 (6 open), and 1 is no phase specified (0 open) [3].

MLLT10 is an inclusion eligibility criterion in 21 clinical trials for hodgkin lymphoma, of which 12 are open and 9 are closed. Of the trials that contain MLLT10 status and hodgkin lymphoma as inclusion criteria, 1 is early phase 1 (0 open), 9 are phase 1 (4 open), 2 are phase 1/phase 2 (2 open), 8 are phase 2 (6 open), and 1 is no phase specified (0 open) [3].

MLLT3 is an inclusion eligibility criterion in 21 clinical trials for hodgkin lymphoma, of which 12 are open and 9 are closed. Of the trials that contain MLLT3 status and hodgkin lymphoma as inclusion criteria, 1 is early phase 1 (0 open), 9 are phase 1 (4 open), 2 are phase 1/phase 2 (2 open), 8 are phase 2 (6 open), and 1 is no phase specified (0 open) [3].

MLLT4 is an inclusion eligibility criterion in 21 clinical trials for hodgkin lymphoma, of which 12 are open and 9 are closed. Of the trials that contain MLLT4 status and hodgkin lymphoma as inclusion criteria, 1 is early phase 1 (0 open), 9 are phase 1 (4 open), 2 are phase 1/phase 2 (2 open), 8 are phase 2 (6 open), and 1 is no phase specified (0 open) [3].

MNX1 is an inclusion eligibility criterion in 1 clinical trial for hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MNX1 status and hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MYC is altered in 1.82% of hodgkin lymphoma patients [2].

MYC is an inclusion eligibility criterion in 6 clinical trials for hodgkin lymphoma, of which 4 are open and 2 are closed. Of the trials that contain MYC status and hodgkin lymphoma as inclusion criteria, 3 are phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 2 are phase 2 (2 open) [3].

MYCN is an inclusion eligibility criterion in 1 clinical trial for hodgkin lymphoma, of which 0 are open and 1 is closed. Of the trial that contains MYCN status and hodgkin lymphoma as inclusion criteria, 1 is phase 1 (0 open) [3].

MYH11 is an inclusion eligibility criterion in 6 clinical trials for hodgkin lymphoma, of which 2 are open and 4 are closed. Of the trials that contain MYH11 status and hodgkin lymphoma as inclusion criteria, 5 are phase 1 (2 open) and 1 is no phase specified (0 open) [3].

NOTCH1 is an inclusion eligibility criterion in 1 clinical trial for hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains NOTCH1 status and hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

NPM1 is an inclusion eligibility criterion in 9 clinical trials for hodgkin lymphoma, of which 6 are open and 3 are closed. Of the trials that contain NPM1 status and hodgkin lymphoma as inclusion criteria, 1 is early phase 1 (0 open), 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 6 are phase 2 (5 open) [3].

NRIP3 is an inclusion eligibility criterion in 21 clinical trials for hodgkin lymphoma, of which 12 are open and 9 are closed. Of the trials that contain NRIP3 status and hodgkin lymphoma as inclusion criteria, 1 is early phase 1 (0 open), 9 are phase 1 (4 open), 2 are phase 1/phase 2 (2 open), 8 are phase 2 (6 open), and 1 is no phase specified (0 open) [3].

NSD1 is an inclusion eligibility criterion in 1 clinical trial for hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains NSD1 status and hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

NUP214 is an inclusion eligibility criterion in 20 clinical trials for hodgkin lymphoma, of which 11 are open and 9 are closed. Of the trials that contain NUP214 status and hodgkin lymphoma as inclusion criteria, 1 is early phase 1 (0 open), 9 are phase 1 (4 open), 2 are phase 1/phase 2 (2 open), 7 are phase 2 (5 open), and 1 is no phase specified (0 open) [3].

NUP98 is an inclusion eligibility criterion in 1 clinical trial for hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains NUP98 status and hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

PBX1 is an inclusion eligibility criterion in 13 clinical trials for hodgkin lymphoma, of which 8 are open and 5 are closed. Of the trials that contain PBX1 status and hodgkin lymphoma as inclusion criteria, 1 is early phase 1 (0 open), 5 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), and 6 are phase 2 (4 open) [3].

PDGFRB is an inclusion eligibility criterion in 1 clinical trial for hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB status and hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

PHF6 is an inclusion eligibility criterion in 1 clinical trial for hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains PHF6 status and hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

PRDM16 is an inclusion eligibility criterion in 1 clinical trial for hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains PRDM16 status and hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RPN1 is an inclusion eligibility criterion in 23 clinical trials for hodgkin lymphoma, of which 14 are open and 9 are closed. Of the trials that contain RPN1 status and hodgkin lymphoma as inclusion criteria, 1 is early phase 1 (0 open), 9 are phase 1 (4 open), 2 are phase 1/phase 2 (2 open), 10 are phase 2 (8 open), and 1 is no phase specified (0 open) [3].

RUNX1 is an inclusion eligibility criterion in 10 clinical trials for hodgkin lymphoma, of which 6 are open and 4 are closed. Of the trials that contain RUNX1 status and hodgkin lymphoma as inclusion criteria, 5 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), 3 are phase 2 (3 open), and 1 is no phase specified (0 open) [3].

RUNX1T1 is an inclusion eligibility criterion in 6 clinical trials for hodgkin lymphoma, of which 2 are open and 4 are closed. Of the trials that contain RUNX1T1 status and hodgkin lymphoma as inclusion criteria, 5 are phase 1 (2 open) and 1 is no phase specified (0 open) [3].

TCF3 is an inclusion eligibility criterion in 13 clinical trials for hodgkin lymphoma, of which 8 are open and 5 are closed. Of the trials that contain TCF3 status and hodgkin lymphoma as inclusion criteria, 1 is early phase 1 (0 open), 5 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), and 6 are phase 2 (4 open) [3].

TET2 is altered in 5.36% of hodgkin lymphoma patients [2].

TET2 is an inclusion eligibility criterion in 1 clinical trial for hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains TET2 status and hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

TP53 is altered in 13.85% of hodgkin lymphoma patients [2].

TP53 is an inclusion eligibility criterion in 21 clinical trials for hodgkin lymphoma, of which 12 are open and 9 are closed. Of the trials that contain TP53 status and hodgkin lymphoma as inclusion criteria, 1 is early phase 1 (0 open), 9 are phase 1 (4 open), 2 are phase 1/phase 2 (2 open), 8 are phase 2 (6 open), and 1 is no phase specified (0 open) [3].

WHSC1 is altered in 1.79% of hodgkin lymphoma patients [2].

WHSC1 is an inclusion eligibility criterion in 2 clinical trials for hodgkin lymphoma, of which 2 are open and 0 are closed. Of the trials that contain WHSC1 status and hodgkin lymphoma as inclusion criteria, 2 are phase 1 (2 open) [3].

WT1 is an inclusion eligibility criterion in 1 clinical trial for hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains WT1 status and hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].